A Study of Tazemetostat on Safety in Participants With Relapsed or Refractory Follicular Lymphoma With Enhancer of Zeste Homolog 2 (EZH2) Gene Mutation in Japan
Clinical trial NCT05228158 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05228158
- Sponsor
- Eisai Co., Ltd.
- Status
- ACTIVE_NOT_RECRUITING
- Study type
- OBSERVATIONAL
- Start date
- 2021-08-16
- Primary completion
- 2028-03-31
- Enrollment
- 145
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.